Sodium feredetate

Identification

Generic Name

Sodium feredetate

DrugBank Accession Number

DB13381

Background

Not Available

Type

Small Molecule

Groups

Approved

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Sodium feredetate (DB13381)

×

Close

Weight

Average: 367.047
Monoisotopic: 366.984071

Chemical Formula

C₁₀H₁₂FeN₂NaO₈

Synonyms

• Feredato de sodio
• Ferédétate de sodium
• Ferric sodium EDTA
• Ferric sodium ethylenediaminetetraacetate
• Ferrostrane
• Ferrostrene
• Monosodium ferric EDTA
• Natrii feredetas
• Sodium feredetate
• Sodium ferric EDTA
• Sodium iron EDTA
• Sodium ironedetate

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Alendronic acid	Sodium feredetate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Almasilate	Almasilate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphate	Aluminium phosphate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Asenapine	Asenapine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.

Food Interactions

• Avoid milk and dairy products.
• Avoid multivalent ions.
• Limit caffeine intake. Food and beverages containing caffeine may reduce iron absorption.
• Take separate from antacids.
• Take with foods containing vitamin C. Foods rich in vitamin C increase the absorption of iron.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Iron	unknown	E1UOL152H7	7439-89-6	XEEYBQQBJWHFJM-UHFFFAOYSA-N
Ferric cation	ionic	91O4LML611	20074-52-6	VTLYFUHAOXGGBS-UHFFFAOYSA-N

International/Other Brands

Calmosine / Sytron

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Bal-Care DHA	Sodium feredetate (25.65 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2850 [iU]/1) + Calcium carbonate (219 mg/1) + Cholecalciferol (840 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (.012 mg/1) + DL-alpha tocopheryl acetate (3 mg/1) + Folic acid (1 mg/1) + Iodine (.223 mg/1) + Iron sucrose (1.35 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (430 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1)	Kit	Oral	Pru Gen Pharmaceuticals	2012-05-01	Not applicable
Bal-Care DHA Essential	Sodium feredetate (25.65 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2850 [iU]/1) + Calcium carbonate (219 mg/1) + Cholecalciferol (840 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (.012 mg/1) + DL-alpha tocopheryl acetate (3 mg/1) + Folic acid (1 mg/1) + Iodine (.223 mg/1) + Iron sucrose (1.35 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (374 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1)	Kit	Oral	Pru Gen Pharmaceuticals	2012-05-01	Not applicable
Cavan-EC SOD DHA	Sodium feredetate (30 mg/1) + Ascorbic acid (130 mg/1) + Beta carotene (3000 [iU]/1) + Calcium (230 mg/1) + Cholecalciferol (410 [iU]/1) + Copper (2 mg/1) + Cyanocobalamin (12 ug/1) + Folic acid (1 mg/1) + Magnesium (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (440 mg/1) + Pyridoxine hydrochloride (28 mg/1) + Riboflavin (4 mg/1) + Thiamine mononitrate (1.8 mg/1) + Vitamin E (30 mg/1) + Zinc (26 mg/1)	Kit	Oral	Seton Pharmaceuticals	2010-01-10	2014-07-15
Cavan-EC SOD DHA	Sodium feredetate (30 mg/1) + Ascorbic acid (130 mg/1) + Beta carotene (3000 [iU]/1) + Calcium carbonate (230 mg/1) + Cholecalciferol (410 [iU]/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (30 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (440 mg/1) + Pyridoxine hydrochloride (28 mg/1) + Riboflavin (4 mg/1) + Zinc oxide (26 mg/1)	Kit	Oral	Physicians Total Care, Inc.	2010-08-24	2013-01-15

Categories

ATC Codes

B03AB03 — Sodium feredetate

• B03AB — Iron trivalent, oral preparations
• B03A — IRON PREPARATIONS
• B03 — ANTIANEMIC PREPARATIONS
• B — BLOOD AND BLOOD FORMING ORGANS

Drug Categories

• Acetates
• Acids, Acyclic
• Amines
• Antianemic Preparations
• Blood and Blood Forming Organs
• Compounds used in a research, industrial, or household setting
• Diamines
• Ethylenediamines
• Iron Chelating Agents
• Iron Compounds
• Iron Preparations
• Iron Trivalent, Oral Preparations
• Parenteral Iron Replacement
• Polyamines
• Sequestering Agents

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Tetracarboxylic acids and derivatives

Direct Parent

Tetracarboxylic acids and derivatives

Alternative Parents

Alpha amino acids / Trialkylamines / Carboxylic acid salts / Amino acids / Organic transition metal salts / Carboxylic acids / Organopnictogen compounds / Organic zwitterions / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

show 2 more

Substituents

Aliphatic acyclic compound / Alpha-amino acid / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative / Organic alkali metal salt / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic salt / Organic sodium salt / Organic transition metal salt / Organic zwitterion / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Tertiary aliphatic amine / Tertiary amine / Tetracarboxylic acid or derivatives

show 14 more

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

organic sodium salt, iron chelate (CHEBI:78292)

Affected organisms

Not Available

Chemical Identifiers

UNII

403J23EMFA

CAS number

15708-41-5

InChI Key

MKWYFZFMAMBPQK-UHFFFAOYSA-J

InChI

InChI=1S/C10H16N2O8.Fe.Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;/q;+3;+1/p-4

IUPAC Name

sodium 5-(carboxymethyl)-3,10,13-trioxo-2,11,12-trioxa-5,8lambda5-diaza-1-ferratetracyclo[6.3.3.0^{1,5}.0^{1,8}]tetradecan-5-ium-8-ylium-1,1-diuide

SMILES

[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4

References

General References

Not Available

External Links

KEGG Drug

D07145

ChemSpider

25555

RxNav

105673

ChEBI

78292

ChEMBL

CHEMBL1705709

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
Not Available	Recruiting	Treatment	Craniosynostosis	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Kit	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0541 mg/mL	ALOGPS
logP	1.45	ALOGPS
logP	-1.5	Chemaxon
logS	-3.9	ALOGPS
pKa (Strongest Acidic)	1.12	Chemaxon
pKa (Strongest Basic)	-7	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	119.03 Å2	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	71.6 m3·mol-1	Chemaxon
Polarizability	26.41 Å3	Chemaxon
Number of Rings	4	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-0fr2-7952000000-5cc18b70a782f1cd2364

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	171.1203687	predicted	DarkChem Lite v0.1.0
[M+H]+	167.7285687	predicted	DarkChem Lite v0.1.0
[M+Na]+	170.4981687	predicted	DarkChem Lite v0.1.0

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 23, 2017 20:40 / Updated at February 21, 2021 18:54